伊布替尼介导心房颤动机制的研究进展

Research progress on the mechanism of ibrutinib mediated atrial fibrillation

伊布替尼是一种新型的抗肿瘤靶向药物,临床发现伊布替尼会增加患者心房颤动(房颤)的易感性。目前房颤的发生机制尚未完全阐明,研究者提出非靶向抑制可能是伊布替尼诱导房颤发生的主要机制。本文对其相关机制进行总结,阐述非心肌细胞在抗肿瘤药物介导心脏毒性研究中的重要地位。

Ibrutinib is a new type of anti-tumor-targeted drug.It has been clinically found to increase the susceptibility of patients with atrial fibrillation.At present,the mechanism of atrial fibrillation has not been fully elucidated.Researchers have proposed that non-targeted inhibition may be the primary mechanism by which ibrutinib induces the occurrence of atrial fibrillation.This review summarizes the relevant mechanisms and illustrates the importance of non-cardiomyocytes in the study of antitumor drug-mediated cardiotoxicity.